Business Context and Reporting Period
Company: MEDICINOVA INC (MNOV)
Filing Type: Form 8-K (Current Report)
Report Date: February 20, 2026
Reporting Period: Year ended December 31, 2025
Context: The Company filed a preliminary, unaudited Japanese report ("Kessan Tanshin") with the Tokyo Stock Exchange. This 8-K incorporates the English translation of that report as Exhibit 99.1. The audited financial statements for the period are not yet available.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice of the filing of preliminary results rather than a disclosure of the specific figures themselves. Investors must refer to the attached Exhibit 99.1 for the actual financial data.
Material Changes
The filing does not contain specific data to compare against prior periods. It explicitly states that the preliminary, unaudited results may differ from the actual results reflected in the final audited financial statements and that such changes may be material.
Guidance, Outlook, and Risks
- Audit Status: The independent registered public accounting firm has not completed the audit and expresses no opinion on the preliminary results.
- Reliability Warning: The preliminary results are subject to completion of financial closing procedures and year-end audit adjustments.
- Legal Status: The information in this report is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting liability exposure compared to filed documents.
Investor Verification Checklist
- Review Exhibit 99.1 (English Translation of Tanshin) for the actual preliminary financial figures.
- Monitor for the release of the final audited financial statements to confirm if material adjustments were made to the preliminary data.
- Verify the Company's liquidity position and cash burn rate once the detailed financial statements are published.